Regulatory approval

Published by the Health Service Executive. Approved

As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), following disease progression on (i) alectinib or ceritinib as the first ALK-targeted treatment or (ii) crizotinib and at least one other ALK-targeted treatment.

This is written in the approval document.

Reimbursement

CDS

Citation

Lorlatinib Therapy, 2021, version number 3, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6889/570_V3_Lorlatinib_therapy_.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	v::ALK	Non-Small Cell Lung Cancer	Lorlatinib

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2019-10-01	Health Service Executive	Indication approved for reimbursement.